Genialis has partnered with the Pancreatic Cancer Action Network (PanCAN) to extend the validation of Genialis' krasID biomarker in pancreatic cancer histology, an AI classifier that predicts response and clinical benefit to KRAS inhibitors across preclinical, clinical, and real-world settings.
The partnership aims to use the Genialis krasID, an AI-powered tool capable of forecasting the response to KRAS inhibitors in various settings. The collaboration is set to advance Genialis krasID as a diagnostic tool to assist in developing new medicines and help doctors plan treatment for pancreatic cancer.
It is also expected to expedite the development of KRAS-targeted therapies to improve treatment outcomes for patients with pancreatic cancer.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.